Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Orladeyo effective in 3 people with HAE of unknown origin

Treatment with Orladeyo (berotralstat) effectively prevented swelling and improved life quality for three people with hereditary angioedema (HAE) with no known disease-causing mutations. “Our results provide the first evidence that [Orladeyo] can be an effective therapy in patients with HAE [who do not have any known mutations],” scientists…

Takhzyro prevented swelling attacks in Japanese HAE patients

Preventive treatment with Takhzyro (lanadelumab) reduced the rate of swelling attacks and improved life quality for Japanese patients with hereditary angioedema (HAE) in a Phase 3 clinical trial. These findings helped to support Takhzyro’s approval in Japan last year for the prevention of swelling attacks in HAE…

FDA approves new generic version of Firazyr for HAE

The U.S. Food and Drug Administration (FDA) has approved a new generic version of Firazyr (icatibant injection) for hereditary angioedema (HAE), Aurobindo Pharma announced in a press release. Like the brand-name medication, the new generic is indicated to treat acute swelling attacks of HAE in adults 18…

Company chosen to commercialize HAE medicine Orladeyo in Turkey

BioCryst Pharmaceuticals is teaming up with Er-Kim Pharmaceuticals to commercialize Orladeyo (berotralstat) in Turkey. Orladeyo is an oral therapy, taken once a day, to prevent swelling attacks with hereditary angioedema (HAE). Er-Kim, based in Istanbul, partners with pharma companies to bring new therapies to markets around…

Case study showcases difficulty with angioedema diagnosis

A woman still doesn’t have a definitive answer as to the underlying cause of her angioedema after more than a decade of recurrent facial swelling, underscoring the difficulties in diagnosing the condition. “This case report demonstrates the challenge of the differential diagnosis of angioedema without wheals,” the researchers wrote…

Clinical hold of deucrictibant for on-demand treatment lifted by FDA

The U.S. Food and Drug Administration (FDA) has lifted its hold on clinical trials of deucrictibant for the on-demand treatment of hereditary angioedema (HAE). The therapy’s developer Pharvaris now expects to resume RAPIDe-2 (NCT05396105), a long-term extension study evaluating PHVS416, an immediate-release capsule formulation of deucrictibant,…

Fewer ER visits for patients on Haegarda, Takhzyro: Study

People with hereditary angioedema (HAE) tend to experience fewer emergency room visits and hospitalizations after starting treatment with Haegarda or Takhzyro (lanadelumab), a new analysis indicates. Despite the decreasing rates, some patients still experience health emergencies while on these therapies, which researchers said highlights the burden of…

PHVS416 found to quickly ease HAE swelling symptoms in trial

On-demand treatment with the experimental oral therapy PHVS416 was found to quickly and effectively ease symptoms of swelling attacks for people with hereditary angioedema (HAE) in a Phase 2 clinical trial. PHVS416 worked within hours of dosing, providing “clinical meaningful” reductions in swelling symptoms, according to researchers. Pharvaris,…